Versatope Therapeutics Start-Up Stadium

10:30 AM–10:45 AM Jun 6, 2019 (US - Eastern)

Hall E, Booth 3971, Level 200


Immuno-therapeutic company that utilizes synthetic biology and bioinformatic computational analysis to create probiotic-derived extracellular vesicles to be used in the delivery of therapeutics for infectious diseases, allergies, and cancer. The vesicles are engineered to modulate immune responses for a variety of diseases and aim to address the current lack of treatments for viral infections, such as influenza, that have both seasonal strains and ever-changing pandemic variants. This technology aims to provide an improved and effective universal influenza vaccine, which could be expanded to other illnesses as well.

Session ID: 548935